Skip to content Skip to footer
Novo-Nordisk

Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients

Shots: Novo Nordisk has reported P-III (REDEFINE 2) trial data assessing CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, QW, SC) vs PBO in 1,206 obese/overweight pts (~102Kg) and type 2 diabetes for 68wks., and followed flexible dosing protocol with 61.9% pts reaching highest dose after 68wks. Trial met its co-1EPs demonstrated 15.7% superior weight loss…

Read more

ThoughtSpot_Igor Zagradanin4

Managing Chronic Conditions: Medication, Supplements, and Personalized Care Plans

Statistics show that at least 129 million people in the United States have a chronic illness. To effectively deal with chronic illnesses, one needs a thorough approach that includes customized supplements and medication. The management of these prolonged conditions requires consistent attention to prevent complexities while ensuring better living standards for patients. Continue reading to learn about…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]